Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2019) [Effective from January 1, 2019]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2017: 100.00
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2017: 100.00
NAAS RATING 2018: 5.38

Int.J.Curr.Microbiol.App.Sci.2019.8(10): 1012-1016
DOI: https://doi.org/10.20546/ijcmas.2019.810.118


Detection of Pre-extensively Drug Resistance (PRE-XDR TB) and Extensively Drug Resistance (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patient by Line Probe Assay
Hiral Gadhavi, Akansha Goyal*, Binita Aring and Summaiya Mullan
Patel colony 6, road no. ½, Jamnagar, Gujarat 361008, India
*Corresponding author
Abstract:

The rate of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has been steadily increasing in developing countries like India. The availability of rapid and reliable methods for the detection of drug resistance to second-line drugs is vital for adequate patient management. MTBDRsl-2 is newer DNA based test recommended by WHO for screening of XDR and Pre XDR patients.MTBDRsl-2 is a rapid, screening method that detects genetic mutation responsible for resistance in second line injectable drugs in tuberculous patients mainly against Flouroquinolones and /or second line injectable drugs. MTBDRsl-2 produces results in just 24-48 hours, as compared to culture methods that takes 3 months or longer. It helps to physician to make line of treatment for confirmed rifampicin resistant or MDR-TB patients into either the shorter MDR-TB regimen or the conventional regimen. This test is the first and only WHO recommended rapid test for detection of additional resistance in MDR-TB patients as well as XDR-TB. Confirmation of Pre XDR and XDR status of patient has to be done by liquid culture DST which requires 1-2 months. As it is rapid it can be helpful in Known MDR patients for further line of management. Total 700 samples are enrolled in the study at Culture and DST Laboratory, Jamanagar Gujrat during Apriln19 to June 19. Only MDR or RR confirmed sputum samples or cultures are tested for second line LPA Version 2. Samples were processed as per standard protocols for Line Probe Assay as per kit instruction. Total 700 MDR Sputum/Culture Samples were tested, out of these 143(20.42%) pre XDR (resistant to either Floroquionolones or one of injectable second line) and 23(3.2%) XDR were found. MDRSl version 2 is rapid, reliable, and accurate Screening method for the identification and detection of Second line drug resistance in M. tuberculosis strains. Early detection of Pre XDR and XDR status helps to manage the tuberculosis patient by helping in deciding line of treatment.


Keywords: Pre XDR, XDR, MTBDRsl LPA.
Download this article as Download

How to cite this article:

Hiral Gadhavi, Akansha Goyal, Binita Aring and Summaiya Mullan. 2019. Detection of Pre-extensively Drug Resistance (PRE-XDR TB) and Extensively Drug Resistance (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patient by Line Probe Assay.Int.J.Curr.Microbiol.App.Sci. 8(10): 1012-1016. doi: https://doi.org/10.20546/ijcmas.2019.810.118